Oncology unit revenues increased 11% operationally in comparison with fourth-quarter 2011. Revenues were positively impacted by the launches of Inlyta and Xalkori in the U.S. and certain other developed markets. Revenues were negatively impacted by approximately $44 million, or 13%, due to the shift in the reporting of international Aromasin revenues to the Established Products unit beginning January 1, 2012.

Consumer Healthcare unit revenues increased 17% operationally in comparison with fourth-quarter 2011, primarily due to the addition of products from the acquisitions of Ferrosan Consumer Health in December 2011 and Alacer Corp. in February 2012 as well as strong growth of Advil and Centrum in the U.S.

Adjusted Expenses (2) , Adjusted Income (2) and Adjusted Diluted EPS (2) Highlights
    Fourth-Quarter Selected Costs and Expenses
($ in millions)

(Favorable)/Unfavorable
  2012   2011   Change    

Foreign

Exchange
  Operational
 
Adjusted Cost of Sales (2) $ 3,106 $ 3,083 1 % 8 % (7 %)
As a Percent of Revenues 20.6 % 19.1 % N/A N/A N/A
Adjusted SI&A Expenses (2) 4,658 5,173 (10 %) (1 %) (9 %)
Adjusted R&D Expenses (2)   2,000     2,318   (14 %) (1 %) (13 %)
 
Total $ 9,764   $ 10,574   (8 %) 1 % (9 %)

See end of text prior to tables for notes.

If you liked this article you might like

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux

The 6 Medications Being Used to Tackle the Opioid Epidemic